Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InventisBio Reports Promising Data from KRAS G12C Trials

publication date: Apr 11, 2022

InventisBio of Shanghai reported promising early data from two trials of its oral KRAS G12C inhibitor, D-1553. In a Phase I international trial in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation, D-1553 produced an objective response rate of 19% and disease control rate of 86%. In a larger 59 patient study, D-1553 achieved an ORR of 40% and a DCR of 90% among NSCLC patients with a KRAS G12C mutation. In 2020, InventisBio completed a $147 million series D financing led by GL Ventures, a Hillhouse affiliate. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital